Stockreport

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults [Yahoo! Finance]

Neurocrine Biosciences, Inc.  (NBIX) 
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: neurocrine.com/about-us/webcasts-presentations
PDF evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an investi [Read more]